Evidence map›Paper›PMID 39751874›Full record

ArticleCancer immunology, immunotherapy : CII2025

CircRNA-loaded DC vaccine in combination with low-dose gemcitabine induced potent anti-tumor immunity in pancreatic cancer model.

Zongyu Cai, Qimuge Wuri, Yang Song, Xueli Qu, Haotong Hu, Simiao Cao, Hui Wu, Jiaxin Wu, Chu Wang, Xianghui Yu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zongyu CaiNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China.
Qimuge WuriNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China.
Yang SongNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China.
Xueli QuNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China.
Haotong HuNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China.
Simiao CaoNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China.
Hui WuNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China.
Jiaxin WuNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China.
Chu WangNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China.
Xianghui YuNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China.
Wei KongNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China.
Haihong ZhangNational Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China. zhanghh@jlu.edu.cn.

Funding

Jilin Provincial Department of Education Scientific Research Project JJKH20231142KJKey R & D Projects of Science and Technology Department of Jilin Province 20230101167JCMajor Projects of Science and Technology Innovation in Changchun City 17YJ002National Science and Technology Major Project of the Ministry of Science and Technology of China 2014ZX09304314-001
6 · The paper itself

Abstract

Although promising, dendritic cell (DC) vaccines may not suffice to fully inhibit tumor progression alone, mainly due to the short expression time of the antigen in DC vaccines, immunosuppressive tumor microenvironment, and tumor antigenic modulation. Overcoming the limitations of DC vaccines is expected to further enhance their anti-tumor effects. In this study, we constructed a circRNA-loaded DC vaccine utilizing the inherent stability of circular RNA to enhance the expression level and duration of the antigen within the DC vaccine. Meanwhile we combined it with gemcitabine and validated their therapeutic efficacy in the Panc02 tumor model. We found that the use of DC vaccine alone can reach a tumor inhibition rate of 69%, and the effect was further enhanced when combined with gemcitabine, reaching a tumor inhibition rate of 89%. The combined treatment achieved a synergistic effect, which not only reduced immunosuppressive Tregs but also induced immunogenic cell death, leading to antigen spreading and reducing immune evasion caused by tumor antigenic modulation. As a result, the survival of the mice was significantly prolonged. Our research provides a promising approach for the clinical treatment of pancreatic cancer.

Indexed as

Cancer VaccinesDendritic CellsDeoxycytidineGemcitabinePancreatic NeoplasmsRNA, CircularAnimalsAntimetabolites, AntineoplasticCell Line, TumorCombined Modality TherapyDisease Models, AnimalFemaleHumansImmunotherapyMiceMice, Inbred C57BLAntimetabolites, AntineoplasticCancer VaccinesDeoxycytidineGemcitabineRNA, CircularCircular RNADC vaccineGemcitabineImmunogenic cell deathImmunotherapy

Identifiers

PMID39751874
PMCPMC11699015

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.